Newswise Feature Channel: Blood

Discovery of Gene Linked to High-Altitude Adaptation May Transform Blood Cancer Care

Huntsman Cancer Institute at the University of Utah — Thu, 12 Dec 2024 21:00:38 EST

Huntsman Cancer Institute researchers have identified a gene variant found in a high-altitude Andean population that may predict severity of diseases and responses to treatments for patients with certain types of blood cancer.

Stephen D. Nimer, M.D., Named Mentor of the Year by the American Society of Hematology

Sylvester Comprehensive Cancer Center — Wed, 11 Dec 2024 14:00:58 EST

Stephen D. Nimer, M.D., has been awarded the American Society of Hematology's Mentor Award for 2024. As director of Sylvester Comprehensive Cancer Center, Nimer lifts up and guides other researchers to create a collaborative environment that drives scientific discovery and quality patient care.

Study Uses Simulated Gastrointestinal Tract to Test Surprising Health Benefit of Sugar Alternative

Toronto Metropolitan University — Wed, 11 Dec 2024 13:30:59 EST

NCCN Announces Funding for a Prostate Cancer Research Project

National Comprehensive Cancer Network(r) (NCCN(r)) — Wed, 11 Dec 2024 08:00:37 EST

The NCCN Oncology Research Program (ORP) announces funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi).

Filling Out the Roadmap for Faster Drug Approvals

Sylvester Comprehensive Cancer Center — Tue, 10 Dec 2024 16:30:21 EST

A new review in Blood Cancer Discovery outlines a key regulatory decision by an FDA committee that greenlights a new biomarker endpoint for accelerated drug approval in multiple myeloma and could cut a decade off the drug development process.

Research Shows New Treatment Could Delay Cancer Progression in Patients with High-Risk Smoldering Multiple Myeloma

Mayo Clinic — Tue, 10 Dec 2024 14:05:51 EST

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

University of Texas MD Anderson Cancer Center — Mon, 09 Dec 2024 20:00:38 EST

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH

Roswell Park Comprehensive Cancer Center — Mon, 09 Dec 2024 19:30:00 EST

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows

Roswell Park Comprehensive Cancer Center — Sun, 08 Dec 2024 16:30:07 EST

Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.

ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma

Sylvester Comprehensive Cancer Center — Sun, 08 Dec 2024 12:00:00 EST

ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers - follicular lymphoma and marginal zone lymphoma.

Multi-Center Study Shows Education Level, Income Impact Access to Stem Cell Transplantation for Acute Myeloid Leukemia Patients

Fred Hutchinson Cancer Center — Sun, 08 Dec 2024 11:10:31 EST

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.

New Research from Children's Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic Leukemia

Children's Hospital of Philadelphia — Sat, 07 Dec 2024 10:00:32 EST

Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes

University of California San Diego — Thu, 05 Dec 2024 15:50:55 EST

New Drug Tested to Reduce Side Effect of 'Half-Matched' Stem Cell Transplants

Washington University in St. Louis — Thu, 05 Dec 2024 14:35:41 EST

Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a clinical trial conducted by researchers at WashU Medicine showed adding the investigational drug itacitinib to standard care for "half-matched" stem cell transplantation may reduce rates of the disease, in which the donor's stem cells attack the patient's healthy tissues.

Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder

Yale Cancer Center/Smilow Cancer Hospital — Thu, 05 Dec 2024 14:10:04 EST

Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous bleeding episodes. Infants with severe hemophilia A (HA) are at risk of brain bleeds, which can lead to serious long-term brain damage. Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A.

U-M Rogel Cancer Center Names 2 New Clinical Research Leaders

Michigan Medicine - University of Michigan — Thu, 05 Dec 2024 13:30:43 EST

The University of Michigan Rogel Cancer Center has named Kyle Cuneo, M.D., its new associate director for clinical research. In addition, a new position of assistant director for clinical research will be filled by John Magenau, M.D.

Tip Sheet: New Insights on RSV and Malaria, Metastatic Breast Cancer Resources for Patients -- and Fred Hutch at ASH

Fred Hutchinson Cancer Center — Thu, 05 Dec 2024 09:00:27 EST

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.

MD Anderson Research Highlights: ASH 2024 Special Edition

University of Texas MD Anderson Cancer Center — Wed, 04 Dec 2024 12:00:04 EST

The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.

NCCN Awards Grants to Improve Care for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Comprehensive Cancer Network(r) (NCCN(r)) — Wed, 04 Dec 2024 08:00:02 EST

The NCCN Oncology Research Program (ORP) announces the awarding of new quality improvement research grants aimed at advancing care for patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Children's Hospital Los Angeles Experts to Present at 2024 American Society of Hematology Meeting

Children's Hospital Los Angeles — Wed, 04 Dec 2024 06:35:50 EST

Children's Hospital Los Angeles faculty will present their latest research on pediatric blood cancers and diseases at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.The annual conference--billed as the world's largest and most comprehensive hematology event--will take place Dec. 7-10. In 2023, ASH attracted more than 32,000 attendees from over 100 countries.